Lon­don's 4BIO Cap­i­tal un­veils first close of $150M fund ded­i­cat­ed to ad­vanced ther­a­pies

Or­chard $OR­TX. Seres $MCRB. Ret­roSense (ac­quired by Al­ler­gan). With sev­er­al high pro­file ex­its un­der their belt, 4BIO Cap­i­tal is out to find more trail­blaz­ers to back in the drug R&D world.

The VC shop has raised $50 mil­lion in the first close of what it hopes to be a $150 mil­lion sec­ond fund at the end of next year. With a fo­cus on ad­vanced ther­a­pies — cell and gene ther­a­py, RNA-based ther­a­py, tar­get­ed ther­a­py, and the mi­cro­bio­me — they will de­vote 60% of the fund to Eu­ro­pean deals from their perch in Lon­don, while spread­ing the rest be­tween Japan and the US, go­ing in­to the Mid­west and the South for promis­ing ideas that might not have re­ceived as much love as those com­ing out of Boston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER